|
1.
|
|
26 p, 520.5 KB |
Combining Molecular, Imaging, and Clinical Data Analysis for Predicting Cancer Prognosis
/
Lobato-Delgado, Barbara (Institut d'Investigació Biomèdica Sant Pau) ;
Priego-Torres, Blanca (Instituto de Investigación e Innovación Biomédica de Cádiz) ;
Sanchez-Morillo, Daniel (Instituto de Investigación e Innovación Biomédica de Cádiz)
Cancer is one of the most detrimental diseases globally. Accordingly, the prognosis prediction of cancer patients has become a field of interest. In this review, we have gathered 43 state-of-the-art scientific papers published in the last 6 years that built cancer prognosis predictive models using multimodal data. [...]
2022 -  10.3390/cancers14133215
Cancers, Vol. 14 Núm. 13 (July 2022) , p. 3215
|
|
|
2.
|
|
23 p, 1.6 MB |
Clustering Treatment Outcomes in Women with Gambling Disorder
/
Lara-Huallipe, Milagros Lizbeth (Hospital Universitari de Bellvitge) ;
Granero, Roser (Universitat Autònoma de Barcelona. Departament de Psicobiologia i de Metodologia de Ciències de la Salut) ;
Fernández-Aranda, Fernando (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Gomez-Peña, Mónica (Hospital Universitari de Bellvitge) ;
Moragas, Laura (Hospital Universitari de Bellvitge) ;
Del Pino-Gutiérrez, Amparo (Universitat de Barcelona) ;
Valenciano-Mendoza, Eduardo (Hospital Universitari de Bellvitge) ;
Mora-Maltas, Bernat (Hospital Universitari de Bellvitge) ;
Etxandi, Mikel (Hospital Universitari de Bellvitge) ;
Menchón Magriñá, José Manuel (Centro de Investigación Biomédica en Red de Salud Mental) ;
Jiménez-Murcia, Susana (Universitat de Barcelona. Departament de Ciències Clíniques)
The rising prevalence of gambling disorder (GD) among women has awakened considerable interest in the study of therapeutic outcomes in females. This study aimed to explore profiles of women seeking treatment for GD based on a set of indicators including sociodemographic features, personality traits, clinical state at baseline, and cognitive behavioral therapy (CBT) outcomes. [...]
2021 - 10.1007/s10899-021-10092-5
Journal of Gambling Studies, Vol. 38 (december 2021) , p. 1469-1491
|
|
|
3.
|
|
15 p, 664.9 KB |
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
/
Wierda, W. G. (University of Texas.) ;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, T. J. (UCSD. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, Sharon (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865
|
|
|
4.
|
|
|
5.
|
|
8 p, 361.9 KB |
Analyzing recurrent events when the history of previous episodes is unknown or not taken into account : proceed with caution
/
Navarro Giné, Albert (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Casanovas Mateu, Georgina (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Alvarado Orellana, Sergio (Facultad de Ciencias de la Salud. Universidad de Tarapacá) ;
Moriña, David (Institut Català d'Oncologia)
Objective Researchers in public health are often interested in examining the effect of several exposures on the incidence of a recurrent event. The aim of the present study is to assess how well the common-baseline hazard models perform to estimate the effect of multiple exposures on the hazard of presenting an episode of a recurrent event, in presence of event dependence and when the history of prior-episodes is unknown or is not taken into account. [...]
Objetivo: A menudo los investigadores en salud pública están interesados en examinar el efecto de varias exposiciones en la incidencia de un evento recurrente. El objetivo de este estudio es evaluar el funcionamiento de los modelos de riesgo basal común al estimar el efecto de múltiples exposiciones sobre el riesgo de presentar un episodio de un evento recurrente, cuando existe dependencia del evento y los antecedentes de los episodios por sujeto son desconocidos o bien no se tienen en cuenta. [...]
2017 - 10.1016/j.gaceta.2016.09.004
Gaceta sanitaria, Vol. 31 Núm. 3 (mayo 2017) , p. 227-234
|
|
|
6.
|
|
22 p, 3.2 MB |
Survival Bias and Crosstalk between Chronological and Behavioral Age : Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging
/
Gimenez-Llort, Lydia (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Marín-Pardo, Daniela (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Marazuela, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hernandez Guillamon, Maria Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca)
New evidence refers to a high degree of heterogeneity in normal but also Alzheimer's disease (AD) clinical and temporal patterns, increased mortality, and the need to find specific end-of-life prognosticators. [...]
2021 - 10.3390/biomedicines9060636
Biomedicines, Vol. 9 (june 2021)
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
13 p, 4.7 MB |
Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis
/
Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rogers, R. B. (Department of Medicine. University of Cambridge. Cambridge Biomedical Campus) ;
Roy, A. (Department of Paediatrics. University of Oxford) ;
Schneider, P. (Princess Maxima Center for Pediatric Oncology) ;
Bardini, Michela (Università degli Studi di Milano-Bicocca) ;
Ballerini, Paola (Pediatric Hematology. A. Trousseau Hospital) ;
Cazzaniga, Giovanni (Centro Ricerca Tettamanti. Department of Pediatrics. University of Milano Bicocca. Fondazione MBBM) ;
Moreno, T. (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Revilla, C. (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Gut, Marta (Universitat Pompeu Fabra) ;
Valsecchi, M. G. (Interfant Trial Data Center. University of Milano-Bicocca) ;
Roberts, I. (MRC Molecular Haematology Unit. MRC Weatherall Institute of Molecular Medicine. University of Oxford) ;
Pieters, R. (Princess Maxima Center for Pediatric Oncology) ;
De Lorenzo, P. (Interfant Trial Data Center. University of Milano-Bicocca) ;
Varela, Ignacio (Instituto de Biomedicina y Biotecnología de Cantabria. Universidad de Cantabria-CSIC) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Stam, R. W. (Princess Maxima Center for Pediatric Oncology) ;
Universitat Autònoma de Barcelona
Bcell acute lymphoblastic leukemia is the commonest childhood cancer. In infants, B-cell acute lymphoblastic leukemia remains fatal, especially in patients with t(4;11), present in ~80% of cases. The pathogenesis of t(4;11)/KMT2A-AFF1 (MLL-AF4) infant B-cell acute lymphoblastic leukemia remains difficult to model, and the pathogenic contribution in cancer of the reciprocal fusions resulting from derivative translocated-chromosomes remains obscure. [...]
2019 - 10.3324/haematol.2018.206375
Haematologica, Vol. 104 Núm. 6 (2019) , p. 1176-1188
|
|
|
10.
|
|
18 p, 4.0 MB |
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
/
Visnes, T. (Sintef Industry. Department of Biotechnology and Nanomedicine) ;
Benítez-Buelga, Carlos (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Cázares-Körner, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Sanjiv, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hanna, Bishoy (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Mortusewicz, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rajagopal, Veera M (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Albers, J. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hagey, D. W. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Bekkhus, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Eshtad, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Baquero, Juan Miguel (Centro Nacional de Investigaciones Oncológicas) ;
Masuyer, G. (University of Bath. Department of Pharmacy and Pharmacology) ;
Wallner, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Müller, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pham, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Göktürk, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rasti, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Suman, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sarno, A. (Sintef Ocean. Department of Environment and New Resources) ;
Wiita, E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Homan, E. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Karsten, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Marimuthu, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Michel, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Koolmeister, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Scobie, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Loseva, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Almlöf, I. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Unterlass, J. E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pettke, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Boström, J. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Pandey, M. (University of Sheffield. Weston Park Cancer Centre) ;
Gad, H. (University of Sheffield. Weston Park Cancer Centre) ;
Herr, P. (University of Sheffield. Weston Park Cancer Centre) ;
Jemth, A. S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
El Andaloussi, S. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Kalderén, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rodriguez-Perales, Sandra (Centro Nacional de Investigaciones Oncológicas) ;
Benítez, J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Krokan, H. E. (Research and Innovation in Central Norway) ;
Altun, M. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Stenmark, P. (Lund University. Department of Experimental Medical Science.) ;
Berglund, U. W. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Helleday, Thomas (University of Sheffield.Weston Park Cancer Centre) ;
Universitat Autònoma de Barcelona
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e. g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. [...]
2021 - 10.1093/nar/gkaa1048
Nucleic acids research, Vol. 48 Núm. 21 (february 2021) , p. 12234-12251
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
